<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097925</url>
  </required_header>
  <id_info>
    <org_study_id>DORAGEN</org_study_id>
    <secondary_id>2018-003921-27</secondary_id>
    <nct_id>NCT04097925</nct_id>
  </id_info>
  <brief_title>Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals</brief_title>
  <official_title>Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacio Lluita Contra la SIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut d'Investigació Biomèdica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacio Lluita Contra la SIDA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the ability of Doravirine to penetrate the genital tract and
      suppress viral replication and provide evidence for the use of Doravirine as part of
      treatment strategies as prevention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

        -  To determine Doravirine concentrations in seminal plasma and cervicovaginal fluid in
           HIV-1 infected male and female individuals receiving antiretroviral therapy (ATR) with
           Doravirine plus Descovy®.

        -  To evaluate HIV-1 viral load in seminal plasma and cervicovaginal fluid in HIV-1
           infected male and female individuals receiving ART with Doravirine plus Descovy®.

      Study Phase:

      Phase II

      Study Design:

      Open label, single arm, single center, prospective study.

      Study Disease:

      HIV-1 infection

      Study Endpoints:

        -  Concentration of Doravirine in seminal plasma and cervicovaginal fluid in HIV-1 infected
           male and female individuals, respectively, 8 weeks after switching to Doravirine plus
           Descovy®.

        -  HIV-1 RNA in seminal plasma and cervicovaginal fluid in HIV-1 infected male and female
           individuals, respectively, 8 weeks after switching to Doravirine plus Descovy®.

      Target Population:

      Male and female adult HIV-1 infected patients receiving standard ART with tenofovir
      alafenamide/emtricitabine (TAF/FTC), tenofovir disoproxil fumarate/emtricitabine or
      abacavir/lamivudine , plus an non-nucleoside reverse transcriptase inhibitor, a boosted
      protease inhibitor or an integrase inhibitor during at least 3 months, with plasma HIV-1 RNA
      suppression (&lt;40 copies/mL) during at least 6 months.

      Number of Subjects Planned:

      15 male and 15 female individuals.

      Study duration:

      16 weeks
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients with Doravirine administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) co-formulated as single tablet (Descovy® TAF/FTC) and administered orally once daily.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Doravirine in seminal plasma fluid</measure>
    <time_frame>8 weeks after switching to Doravirine plus TAF/FTC</time_frame>
    <description>Concentration of Doravirine in seminal plasma fluid in HIV-1 infected male individuals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Doravirine in cervicovaginal fluid</measure>
    <time_frame>8 weeks after switching to Doravirine plus TAF/FTC</time_frame>
    <description>Concentration of Doravirine in cervicovaginal fluid in HIV-1 infected female individuals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification number of copies / mL of HIV in seminal plasma</measure>
    <time_frame>8 weeks after switching to Doravirine plus TAF/FTC</time_frame>
    <description>Quantification of copies / mL of HIV in seminal plasma in HIV-1 infected male individuals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification number of copies / mL of HIV in cervicovaginal fluid</measure>
    <time_frame>8 weeks after switching to Doravirine plus TAF/FTC</time_frame>
    <description>Quantification of copies / mL of HIV in cervicovaginal fluid in HIV-1 infected female individuals</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Doravirine + Descovy® TAF/FTC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) co-formulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine</intervention_name>
    <description>Doravirine 100 mg tablet</description>
    <arm_group_label>Doravirine + Descovy® TAF/FTC</arm_group_label>
    <other_name>MK-1439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Descovy</intervention_name>
    <description>Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet</description>
    <arm_group_label>Doravirine + Descovy® TAF/FTC</arm_group_label>
    <other_name>TAF/FTC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Asymptomatic, HIV-1 infected individuals ≥ 18 years of age.

          2. Be on a stable ART consisting of TAF/FTC, tenofovir disoproxil fumarate/emtricitabine
             or abacavir/lamivudine, plus an non-nucleoside reverse transcriptase inhibitor, a
             boosted protease inhibitor or an integrase inhibitor, continuously for at least 3
             consecutive months preceding the screening visit.

          3. Plasma HIV-1 RNA &lt;40 copies/mL for at least 6 months at the Screening visit.

          4. Signed and dated written informed consent prior to inclusion.

          5. Female Subjects of Childbearing Potential must agree to utilize a highly effective
             method of contraception during heterosexual intercourse from the screening visit
             throughout the duration of the study.

        Exclusion Criteria:

          1. Severe hepatic impairment (Child-Pugh Class C)

          2. Ongoing malignancy

          3. Active opportunistic infection

          4. Resistance to any of the antiretroviral (ARV) included in the study or history of
             virologic failure with risk of resistance selection to any of the study drugs.

          5. Any verified Grade 4 laboratory abnormality

          6. ALT or AST ≥ 3xULN and/or bilirubin ≥ 1.5xULN

          7. Severe renal impairment (Estimated creatinine filtration rate &lt;50mL/min).

          8. Females who are pregnant (as confirmed by positive serum pregnancy test) or
             breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Podzamczer Palter, PhD Chief</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arkaitz Imaz, PhD</last_name>
    <phone>+34932607667</phone>
    <phone_ext>2883</phone_ext>
    <email>aimaz@bellvitgehospital.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Manuel Tiraboschi, PhD</last_name>
    <phone>+34932607667</phone>
    <phone_ext>2885</phone_ext>
    <email>jmtiraboschi@bellvitgehospital.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Morenilla</last_name>
      <phone>+34933359011</phone>
      <phone_ext>2913</phone_ext>
      <email>smorenilla@bellvitgehospital.cat</email>
    </contact>
    <contact_backup>
      <last_name>Laura Acerete</last_name>
      <phone>+34933359011</phone>
      <phone_ext>2876</phone_ext>
      <email>lacerete@bellvitgehospital.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Podzamczer, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arkaitz Imaz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Manuel Tiraboschi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacio Lluita Contra la SIDA</investigator_affiliation>
    <investigator_full_name>Daniel Podzamczer</investigator_full_name>
    <investigator_title>Chief of the HIV and STD Unit (Infectious Disease Service)</investigator_title>
  </responsible_party>
  <keyword>Doravirine</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

